Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...

Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European Medicines Agency’s (EMA) CHMP for use in individuals aged six months and older.

Hong Kong will have another choice for a Covid-19 vaccine targeting the Omicron variant, with drug maker BioNTech offering to make its second-generation jabs available in the city as early as ...

For those wanting the home test kit, free rapid antigen tests will continue to be available through local public health units ...

mRNA), and granted emergency use authorization for individuals 6 months through 11 years of age (Pfizer-BioNTech COVID-19 Vaccine) of the companies’ Omicron KP.2-adapted 2024-2025 NEW YORK ...

Gov. Ron DeSantis’ controversial surgeon general continues to advise against mRNA COVID-19 vaccines. The newest vaccine is ...

1 sublineages, including KP.2, KP.3 and LB.1, compared with the companies’ Omicron XBB.1.5 adapted Covid-19 vaccine .3 The Covid-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary ...

BioNTech SE (BNTX – Research Report), the ... This vaccine version is adapted to the Omicron KP.2 variant, which is in line with FDA recommendations, and it has shown a significantly improved ...